Immutep (Prima Biomed) | PRR | Pharmaceuticals & biotechnology
Performance | Valuation | Growth | Summary | Balance Sheet | Income Statement | Cash Flow
A$ in Million. Fiscal year ends in June. Figures are consolidated and restated.
2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | ||
Cash and cash equiva... | 6 | 46 | 17 | 22 | 14 | 7 | 21 | 12 | |
Short-term investment | 0 | 0 | 21 | 8 | 9 | 0 | 0 | 0 | |
Accounts receivables | 0.08 | 0.04 | 0.28 | 0.2 | 0.2 | 0.32 | 0.17 | 2 | |
Inventories | 0 | 0.21 | 0.19 | 0 | 0 | 0 | 0 | 0 | |
Deferred income taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Other current assets | 11 | 11 | 2 | 2 | 1 | 0.95 | 0.62 | 1 | |
Total current assets | 17 | 57 | 41 | 32 | 25 | 8 | 22 | 16 | |
Gross property plant... | 0.1 | 0.12 | 0.48 | 0.83 | 0.58 | 0.3 | 0.03 | 0.02 | |
Accumulated Depriciat... | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Net property, plant and Eq... | 0.1 | 0.12 | 0.48 | 0.83 | 0.58 | 0.3 | 0.03 | 0.02 | |
Work in Progress | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Miscellaneous Investment | 0.57 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Deferred income taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Intangible assets | 0.5 | 0.46 | 0.23 | 0.17 | 0.12 | 23 | 21 | 19 | |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Other long-term assets | 0.3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Total non-current assets | 1 | 0.58 | 0.71 | 1 | 0.69 | 23 | 21 | 19 | |
Total assets | 18 | 58 | 42 | 33 | 25 | 31 | 43 | 35 | |
Short-term debt | 0.6 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | |
Accounts Payable... | 1 | 2 | 3 | 3 | 3 | 3 | 1 | 3 | |
Provisions | 0.02 | 0.07 | 0.12 | 0.03 | 0.1 | 0.08 | 0.03 | 0.04 | |
Taxes Payable | 0 | 0 | 0 | 0.03 | 0.02 | 0.02 | 0.02 | 0 | |
Deferred Revenues | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Capital Leases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Other current liabilities | 0.08 | 0 | 1 | 0.03 | 0 | 0 | 0 | 0 | |
Total current liabilities | 2 | 3 | 4 | 4 | 3 | 4 | 1 | 3 | |
Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 6 | |
Investments Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Deferred tax liabilities | 0 | 0 | 0 | 0 | 0 | 2 | 0.69 | 0 | |
Provisions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Capital Leases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Other longterm liabilities | 0 | 0 | 0.01 | 0.01 | 0.01 | 0.04 | 0.04 | 0.02 | |
Total non-current liabilities | 0 | 0 | 0.01 | 0.01 | 0.01 | 2 | 6 | 6 | |
Total liabilities | 2 | 3 | 4 | 4 | 3 | 6 | 7 | 8 | |
Share Capital | 75 | 135 | 137 | 142 | 149 | 180 | 195 | 195 | |
Share premium | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Retained earnings | 0.02 | 0 | 0.18 | 2 | 2 | 5 | 63 | 63 | |
Accumulated other equity | -59 | -80 | -100 | -115 | -128 | -160 | -222 | -232 | |
Preferred Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Total Equity | 16 | 55 | 37 | 29 | 23 | 25 | 35 | 27 | |
Total Liabilities and Equity | 18 | 58 | 42 | 33 | 25 | 31 | 43 | 35 | |
Cash per Share | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | |
Cash, Current Inv Per share | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade |